Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and...
- Mechanism
- Curator reviewed
Eldecalcitol [1a,25-DIHYDROXY-2ß-(3-hydroxypropoxy)vitamin D3] is an analog of 1a,25-dihydroxyvitamin D3 [1,25(OH)2D3], bearing a hydroxypropoxy residue at the 2b position. Eldecalcitol is also effective in increasing bone mass and was able to enhance bone strength in rodents. It binds to the vitamin D receptor (VDR) with less affinity but binds to vitamin D-binding protein with higher affinity than 1,25(OH)2D, showing a long half-life in plasma.
- Primary indication
- Investigated for use/treatment in osteoporosis.Curator reviewed
- Formula / weight
- C30H50O5 · 490.725 g/mol (avg)
- Code names
- ED-71
Resolves to
FZEXGDDBXLBRTD-AYIMTCTASA-NSMILES[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)[C@@H](OCCCO)[C@H](O)C1=C)[C@H](C)CCCC(C)(C)OWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Eldecalcitol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account